Press Releases

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

Posted on June 27, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022

Posted on May 27, 2022

INOVIO to Present at Jefferies 2022 Healthcare Conference

Posted on May 23, 2022

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

Posted on May 10, 2022

INOVIO Reports First Quarter 2022 Financial Results and Program Developments

Posted on May 10, 2022

INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022

Posted on April 26, 2022

INOVIO to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Posted on March 8, 2022

INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results

Posted on March 1, 2022

INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

Posted on February 15, 2022

INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

Posted on December 14, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.